pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

7,878 catalysts · 4,779 phase readout · 2,339 8k filing · 286 earnings · 271 pdufa · 166 phase 2 completion · 71 phase 1 completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 0 catalysts2026-07-23: 0 catalysts2026-07-24: 1 catalyst2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type
  • phase readout4,779
  • 8k filing2,339
  • earnings286
  • pdufa271
  • phase 2 completion166
  • phase 1 completion71
  • phase 2 initiation54
  • phase 1 initiation39
  • phase 1 2 completion33
  • phase 0 trial completion23
  • therapy area
    • Oncology139
    • Infectious Disease41
    • Cardiology37
    • Immunology32
    • Dermatology27
    • Pulmonology19
    • Women's Health16
    • Ophthalmology15
    • Pain12

    Week of Apr 27, 2026

    50
    ›Apr 30, 2026phase 2 completion85d agoGandhi Medical College & Hospital — dexmedetomidine (Phase II Trial Completion)dexmedetomidine

    Therapy area: Oncology. Indication: Malignant Neoplasms

    full page →dexmedetomidine →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoZhejiang Provincial People's Hospital — telitacicept (Phase II Trial Completion)telitacicept

    Therapy area: Immunology. Indication: Rheumatoid Arthritis

    full page →telitacicept →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoDalian Municipal Central Hospital — dexamethasone (Phase II Trial Completion)dexamethasone

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →dexamethasone →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoSmt.B.K.Shah Medical Institute & Research Centre & Dhiraj Hospital — dexmedetomidine (Phase II Trial Completion)dexmedetomidine

    Therapy area: Central Nervous System. Indication: Sedation

    full page →dexmedetomidine →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoKSO Corp — undisclosed plant extract (Phase II Trial Completion)undisclosed plant extract

    Therapy area: Genito Urinary System. Indication: Unspecified Genito Urinary Disorders

    full page →undisclosed plant extract →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoThe First Affiliated Hospital of Guangxi Medical University — fospropofol disodium (Phase II Trial Completion)fospropofol disodium

    Therapy area: Central Nervous System. Indication: Sedation

    full page →fospropofol disodium →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoQinghai Provincial Xining Third People's Hospital — amoxicillin (Phase II Trial Completion)amoxicillin

    Therapy area: Gastrointestinal, Infectious Disease. Indication: Gastritis, Helicobacter pylori Infections

    full page →amoxicillin →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoQilu Pharmaceutical Co Ltd — iruplinalkib (Phase II Trial Completion)iruplinalkib

    Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer

    full page →iruplinalkib →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoTufts Medical Center — phytonadione (Phase II Trial Completion)PHYTONADIONE

    Therapy area: Musculoskeletal Disorders. Indication: Osteoarthritis

    full page →PHYTONADIONE →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoDanone Research & Innovation — (prebiotics + probiotic + protein blend + micronutrient blend) (Phase II Trial Completion)(prebiotics + probiotic + protein blend + micronutrient blend)

    Therapy area: Central Nervous System, Metabolic Disorders. Indication: Ageing, Unspecified Psychiatric Disorders

    full page →(prebiotics + probiotic + protein blend + micronutrient blend) →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoNational Health and Medical Research Council — docosahexaenoic acid (Phase II Trial Completion)docosahexaenoic acid

    Therapy area: Women's Health. Indication: Labor And Delivery

    full page →docosahexaenoic acid →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoChildren’s Hospital of Chongqing Medical University — iKids-Growth (Phase II Trial Completion)iKids-Growth

    Therapy area: Hormonal Disorders. Indication: Shox Deficiency

    full page →iKids-Growth →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoRegeneron Pharmaceuticals Inc — cemiplimab (Phase II Trial Completion)cemiplimab

    Therapy area: Oncology. Indication: Adenocarcinoma, Colon Cancer, Colorectal Cancer

    full page →cemiplimab →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoIntas Pharmaceuticals Ltd — olaparib (Phase II Trial Completion)olaparib

    Therapy area: Oncology. Indication: Breast Cancer, Castration-Resistant Prostate Cancer (CRPC), Epithelial Ovarian Cancer, Fallopian Tube Cancer, Metastatic Breast Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Peritoneal Cancer, Solid Tumor

    full page →olaparib →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoGuy's and St Thomas' NHS Foundation Trust — autologous regulatory T cells (Phase II Trial Completion)autologous regulatory T cells

    Therapy area: Genito Urinary System, Immunology. Indication: End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Kidney Transplant Rejection

    full page →autologous regulatory T cells →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoMerck & Co Inc — pembrolizumab (Phase II Trial Completion)pembrolizumab

    Therapy area: Oncology. Indication: Glioblastoma Multiforme (GBM), Gliosarcoma

    full page →pembrolizumab →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoAustralasian Gastro-Intestinal Trials Group — valproate sodium (Phase II Trial Completion)VALPROATE SODIUM

    Therapy area: Oncology. Indication: Colorectal Cancer, Metastatic Colorectal Cancer

    full page →VALPROATE SODIUM →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoBrigham and Women's Hospital — dupilumab (Phase II Trial Completion)dupilumab

    Therapy area: Ear Nose Throat Disorders, Respiratory. Indication: Asthma, Nasal Polyps (Nasal Polyposis), Rhinosinusitis

    full page →dupilumab →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoZhejiang University Hospital One — serplulimab (Phase II Trial Completion)serplulimab

    Therapy area: Oncology. Indication: Adenocarcinoma Of The Gastroesophageal Junction, Gastric Cancer

    full page →serplulimab →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoMerck & Co Inc — tulisokibart (Phase II Trial Completion)tulisokibart

    Therapy area: Immunology, Respiratory. Indication: Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Systemic Sclerosis (Scleroderma)

    full page →tulisokibart →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoThe National Institute of Diabetes and Digestive and Kidney Diseases — undisclosed anti-diuretics (Phase II Trial Completion)undisclosed anti-diuretics

    Therapy area: Genito Urinary System. Indication: End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)

    full page →undisclosed anti-diuretics →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini — dexamethasone (Phase II Trial Completion)dexamethasone

    Therapy area: Central Nervous System, Musculoskeletal Disorders. Indication: Bone Fracture, Post-Operative Pain

    full page →dexamethasone →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoGerman Sport University Cologne — polyphenol-rich cocoa extract (Phase II Trial Completion)polyphenol-rich cocoa extract

    Therapy area: Cardiovascular. Indication: Idiopathic (Essential) Hypertension

    full page →polyphenol-rich cocoa extract →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoGuangzhou Panyu Central Hospital — aumolertinib mesylate (Phase II Trial Completion)aumolertinib mesylate

    Therapy area: Oncology. Indication: Lung Adenocarcinoma, Non-Small Cell Lung Cancer

    full page →aumolertinib mesylate →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoBuck Institute for Research on Aging — Glylo (Phase II Trial Completion)Glylo

    Therapy area: Metabolic Disorders. Indication: Ageing

    full page →Glylo →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoPharmenterprises — XC-243 (Phase II Trial Completion)XC-243

    Therapy area: Genito Urinary System. Indication: Cystitis

    full page →XC-243 →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoSichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital — bupivacaine liposome (Phase II Trial Completion)bupivacaine liposome

    Therapy area: Musculoskeletal Disorders. Indication: Bone Fracture

    full page →bupivacaine liposome →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoMedanta - The Medicity — centhaquine citrate (Phase II Trial Completion)centhaquine citrate

    Therapy area: Cardiovascular, Other Diseases. Indication: Hemorrhagic Shock, Injury, Trauma

    full page →centhaquine citrate →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoDiabete Quebec — insulin (Phase II Trial Completion)insulin

    Therapy area: Metabolic Disorders. Indication: Hyperglycemia, Type 1 Diabetes (Juvenile Diabetes)

    full page →insulin →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoShenzhen Eye Hospital — umbilical cord mesenchymal stem cells derived apoptotic vesicles (Phase II Trial Completion)umbilical cord mesenchymal stem cells derived apoptotic vesicles

    Therapy area: Ophthalmology. Indication: Keratoconjunctivitis Sicca (Dry Eye)

    full page →umbilical cord mesenchymal stem cells derived apoptotic vesicles →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoSun Yat-Sen University Hospital 5 — carboplatin (Phase II Trial Completion)Carboplatin Pfizer

    Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)

    full page →Carboplatin Pfizer →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoXiangyang First People's Hospital — sodium bicarbonate (Phase II Trial Completion)SODIUM BICARBONATE

    Therapy area: Undisclosed. Indication: Unspecified

    full page →SODIUM BICARBONATE →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoNigde Omer Halisdemir University — ozonated oil (Phase II Trial Completion)ozonated oil

    Therapy area: Dermatology, Gastrointestinal, Immunology. Indication: Inflammation, Inguinal Hernia, Wounds

    full page →ozonated oil →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoTaian City Central Hospital — alfentanil (Phase II Trial Completion)alfentanil

    Therapy area: Women's Health. Indication: Unspecified Gynecological Disorders

    full page →alfentanil →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoAssaf Harofeh Medical Center — acetaminophen (Phase II Trial Completion)acetaminophen ER

    Therapy area: Central Nervous System. Indication: Pain

    full page →acetaminophen ER →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoMayo Clinic — kava (Phase II Trial Completion)kava

    Therapy area: Central Nervous System. Indication: Unspecified Psychiatric Disorders

    full page →kava →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoShanghai Longfine Biotechnology Co Ltd — toripalimab (Phase II Trial Completion)toripalimab

    Therapy area: Oncology. Indication: Triple-Negative Breast Cancer (TNBC)

    full page →toripalimab →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoCancer Institute and Hospital Chinese Academy of Medical Sciences — lenvatinib (Phase II Trial Completion)lenvatinib

    Therapy area: Cardiovascular, Oncology. Indication: Hepatocellular Carcinoma, Thrombosis, Venous (Vein) Thrombosis

    full page →lenvatinib →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoSheikh Zayed Medical College Rahim Yar Khan — ursodeoxycholic acid (Phase II Trial Completion)ursodeoxycholic acid

    Therapy area: Gastrointestinal, Metabolic Disorders. Indication: Hyperbilirubinemia, Jaundice

    full page →ursodeoxycholic acid →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoCelerion Inc — ORX-750 (Phase II Trial Completion)ORX-750

    Therapy area: Central Nervous System. Indication: Idiopathic Hypersomnia (IH), Narcolepsy, Type 1 Narcolepsy (Narcolepsy with Cataplexy), Type 2 Narcolepsy (Narcolepsy without Cataplexy)

    full page →ORX-750 →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoDow University of Health Sciences — simvastatin (Phase II Trial Completion)simvastatin

    Therapy area: Mouth and Dental Disorders. Indication: Unspecified Mouth and Dental Disorders

    full page →simvastatin →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoMedical University of Gdansk — apixaban (Phase II Trial Completion)apixaban ODT

    Therapy area: Cardiovascular, Oncology. Indication: Diffuse Large B-Cell Lymphoma, Hematological Tumor, Leukemia, Lymphoma, Multiple Myeloma (Kahler Disease), Myeloproliferative Disorders, Pulmonary Embolism, Thromboembolic Disease, Venous Thromboembolism

    full page →apixaban ODT →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoNeurodawn Pharmaceutical Co Ltd — Loberamisal (Phase II Trial Completion)Loberamisal

    Therapy area: Cardiovascular. Indication: Acute Ischemic Stroke, Cerebral Infarction (Brain Infarction)

    full page →Loberamisal →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoXijing Hospital — pertuzumab + trastuzumab (Phase II Trial Completion)pertuzumab + trastuzumab

    Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer), Triple-Negative Breast Cancer (TNBC)

    full page →pertuzumab + trastuzumab →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoLTR Pharma Ltd — vardenafil (Phase II Trial Completion)vardenafil

    Therapy area: Central Nervous System. Indication: Erectile Dysfunction

    full page →vardenafil →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoCentrum Clinic IVF Center — follitropin (Phase II Trial Completion)follitropin

    Therapy area: Women's Health. Indication: Female Infertility

    full page →follitropin →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoSohag University — ephedrine (Phase II Trial Completion)ephedrine

    Therapy area: Cardiovascular. Indication: Hypotension

    full page →ephedrine →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoAthletic Greens International Inc — undisclosed mineral supplement (Phase II Trial Completion)undisclosed mineral supplement

    Therapy area: Central Nervous System. Indication: Sleep Disorders

    full page →undisclosed mineral supplement →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoNational Institutes of Health — metformin hydrochloride ER (Phase II Trial Completion)metformin hydrochloride ER

    Therapy area: Cardiovascular, Genito Urinary System, Infectious Disease. Indication: Acute Renal Failure (ARF) (Acute Kidney Injury), Sepsis, Septic Shock

    full page →metformin hydrochloride ER →source: globaldata
    ›Apr 30, 2026phase 2 completion85d agoAstraZeneca Plc — tozorakimab (Phase II Trial Completion)tozorakimab

    Therapy area: Respiratory. Indication: Chronic Obstructive Pulmonary Disease (COPD)

    full page →tozorakimab →source: globaldata
    ← prev
    page 11 of 158
    next →
    $MRK130.48+2.36%
    $MRK130.48+2.36%
    $AZN168.27-0.86%
    $REGN651.91+0.11%